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Abstract
Background: In recent decades atypical antipsychotics have increased treatment options available for
schizophrenia, however there is conflicting evidence concerning the trade-off between clinical efficacy and side
effects for the different classes of antipsychotics. There has been a consistent increase in atypical antipsychotic
prescribing compared to typical, despite evidence showing that neither class is superior. This leads to the question
of whether prescribers are selective in their uptake of research evidence and clinical guidelines and if so, what
influences their choice.. This study aims to identify the factors that contribute to the prescribing choice and how
these can be used to aid knowledge translation and guideline implementation.
Methods: A thematic analysis study was conducted using data from 11 semi-structured interviews with clinicians
with experience in prescribing for schizophrenia.
Results: The analysis identified five themes underpinning prescribing behaviour: (1) ownership and collaboration;
(2) compromise; (3) patient involvement; (4) integrating research evidence; and (5) experience.
Conclusion: The themes mapped to various degrees onto current models of evidence-based decision making and
suggest that there is scope to re-think the guideline implementation frameworks to incorporate recurring themes
salient to clinicians who ultimately use the guidelines. This will further translation of future evidence into clinical
practice, accelerating clinical progress.
Keywords: Antipsychotics, Schizophrenia, Guidelines, Qualitative, Evidence based medicine
Background
NICE Clinical Guideline 82 [1] and the subsequent Clinical
Guideline 178 “Psychosis and schizophrenia in adults: pre-
vention and management” [2] replacing the initial NICE
Clinical Guideline 1 “Schizophrenia: Core Interventions in
the Treatment and Management of Schizophrenia in Pri-
mary and Secondary Care” [3] firmly advise that no prefer-
ence should be given to typical or atypical antipsychotics in
the treatment and management of schizophrenia.
However, research suggests that atypical antipsychotics
remain the prevalent choice of medication: Marston et
al. [4] found that atypical antipsychotics accounted for
66.7% of the total antipsychotics prescribing, and the
Prescription Cost Analysis data shows a continuous
decrease in typical and increase in atypical antipsychotic
prescriptions between 2006 and 2014 [5].
This paper aims to understand why atypical antipsy-
chotics continue to be the ubiquitous prescribing practice
despite robust research evidence indicating no clinical effi-
cacy advantages (apart from clozapine) [6–9]. While many
trials do not report a difference in clinical efficacy there is
a well-recognised difference in side effects between typical
and atypical antipsychotics [9]. Typical antipsychotics are
associated with extrapyramidal side effects, whereas atyp-
ical antipsychotics are associated with metabolic side
effects [6, 10]. It has been found that these side effects are
dose related [9]. Side effects have been found to be an im-
portant factor in prescribers decision making [11], which
could explain the increased prescription rate of atypical
antipsychotics as there side effects are viewed as more
favourable and the avoidance of extrapyramidal side
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effects may have encouraged more prescribers to use atyp-
ical antipsychotics [12].
Although the published literature [11, 13, 14] offers insight
into clinical decision making, an exploration of how the
contributing factors map onto the evidence-based medicine
(EBM) models was needed.
Clinical decision-making is informed by the principles of
EBM. A recent model of evidence based decision-making
states that there should be a balance between four main fac-
tors: research evidence; patient’s preferences; the clinical sce-
nario and the clinical environment. Clinical expertise is
needed to tie these four parts together and assess the best
treatment options for the patient [15].
Banning [13] found that inexperienced practitioners rely
more on guidelines than those with experience, in whom
decision-making becomes more intuitive. According to Bate
[14], information is processed using two independent cogni-
tive systems. System one is described as ‘an intuitive, fast,
automatic and effortless process,’ in contrast to system two
which is described as ‘careful, rational analysis and evalu-
ation of available information’. The development of system
one depends on experience and clinical teaching, whereas
system two relies on the insight into the limitations of their
knowledge. It is recognised that there is a four-stage con-
scious competence model of learning in which there is a
cycle between system one and two depending on one’s
awareness of their competency in a particular skill.
Recent research identifies barriers to guideline implemen-
tation, including organisation resources, characteristics of
the healthcare professionals and their perception of the
guidelines and treatment [16]. Recognising the barriers that
prevent the delivery of optimal evidence-based care is
important as an inability to adequately utilise research leads
to ineffective care [17]. However, barriers to guideline imple-
mentation and knowledge translation could not account for
all factors that may contribute to the prescribing trends.
This article aims to explore what other factors may be in-
volved in the decision-making in prescribing antipsychotics,
by using thematic analysis to investigate clinicians’ own nar-
rative when asked to rationalise their choice of prescribing.
Methods
Recruitment and participants
The study used a purposive sampling and a data satur-
ation strategy. Eleven clinicians were recruited from a
Health Board in Wales, and the inclusion criteria was
limited to experience in antipsychotic prescribing for
schizophrenia, and willingness to take part in the study.
The sample included two nurse prescribers, three junior
doctors and six consultants (two of which professors
with significant experience and seniority). This heteroge-
neous sample meant that a wide range of views were
explored. Although the sample may not be representa-
tive of the UK, this was not deemed to be an issue of
significance in this exploratory, hypothesis generating
qualitative study. The amount of information obtained
determines the number of participants needed; as many
themes as possible are produced and when no new
themes emerge, data saturation has been reached and no
more participants are required [18]. Recruitment of par-
ticipants stopped when no new themes emerged.
Data collection
The semi-structured interviewers conducted required partic-
ipants to consider two identical case vignettes - which were
designed to describe patients with presentations suggestive
of schizophrenia. Participants were required to describe their
clinical reasoning but were not explicitly informed that the
study investigated factors that contributed to their choice of
antipsychotic, to avoid leading. Participants were asked to
work through the case vignettes in a ‘think-aloud’ format, a
method requiring the subject to explicitly verbalise their
thinking process [19]. This method was chosen as it allows
greater insight into the immediate thoughts; research has
shown that the think-aloud technique is one of the most
valid tools for assessing higher level thought processes as
well as for comparing participants performing the same task
[19]. For this method to be effective, the vignette used must
be complex enough to remove the possibility of the candi-
date completing it automatically. These interviews were re-
corded and transcribed verbatim.
Data analysis
The interviews were analysed using deductive thematic
analysis, a qualitative method that results in the identifica-
tion of themes throughout a data set. It allows the analysis
of the commonalities between different discussions of the
same topic [20]. The thematic analysis method followed
the six phases identified by Braun and Clarke [21]. The
coding was carried out manually and moderated to ensure
their consistency and validity in relation to the data.
Inter-rater reliability achieved a similarity of at least 80%
(by simple percent agreement) between the researchers
which suggests that the themes were reliable.
A code is a label that can be assigned to parts of
the interview with similar meaning in the process of
coding [22]. Each interview was coded individually
using the transcribed copy of the interview and the
recording. The creation of codes helped to reduce
the volume of data and created a new structure for
analysis. In this study, semantic codes were identified
in order to provide a description of all the data.
Semantic codes refer to the surface meaning of the
data [20] Coding was completed using a cutting and
sorting method [23]. From this process, a coding
framework was generated (Appendix), which led to
families of codes coalescing to form the themes
presented below.
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Results
Five main themes emerged during thematic analysis of
the data: (1) ownership and collaboration; (2) comprom-
ise; (3) patient involvement; (4) integrating research
evidence; and (5) experience.
Patient involvement
This theme explores firstly whether the participants consider
patients in their decision-making and secondly whether this
involvement appears to be tokenistic or true. According to
guidelines, patients should be included in treatment deci-
sions. The question can then be asked does a participant
conscientiously following guidelines make them more likely
to include a patient’s opinions.
Most participants recognised the importance of discuss-
ing treatment options and side-effects with the patients,
“if you get a relationship right with the patient, your
likelihood of success is better” (Participant nine).
However, the ways in which participants engaged with
patients varied. Participant nine states that, “the pharmacist
comes in and is usually very happy to discuss with the pa-
tient” indicating they would not personally discuss these is-
sues with the patient.
Other participants suggest that while they are happy
to hear the patient’s views they will overrule their views
if they disagree with what they feel is best.
“I’ve got more psychiatric experience than the patient
has…what I would do here, I would first try
Amisulpride” (Participant eight).
This participant did not mention guidelines at any
point during their interview.
Participant ten discusses and follows NICE guidelines, de-
scribing the discussion with the patient as a “negotiation”.
This is important to them as they recognise that many pa-
tients do not take the medication that they are prescribed.
Other participants disagree; while they believe that the pa-
tient should be consulted they think that too much choice
could be viewed as uncertainty about antipsychotics:
“the patient may be left with the idea that erm, we’re
not one hundred percent certain, you know, which will
be effective and which won’t be really” (participant 6).
During their interview, they discuss the Maudsley
guidelines but not NICE guidelines.
Ownership and collaboration
It was found that participants took varying levels of re-
sponsibility for parts of the prescribing process depend-
ing on the aspect of care they were discussing.
Sub-theme 1: Taking full responsibility
Some of the participants took full responsibility for the
care of the patient, as indicated by use of the first person
singular. For example, participant one consistently uses
‘I’ when gathering information and forming a diagnosis.
They also take ownership of the risks associated with
prescribing.
“So now I can change the Olanzapine, but I can’t
change the diabetes” (Participant 1).
Sub-theme 2: Sharing responsibility
Other participants indicated they would share responsibil-
ity of patient care, as indicated by using the first person
plural. For example, when discussing risk management,
participant one says “we need to manage”. Participant two
uses “I” when planning the assessment and their immedi-
ate plan, however they use “we” when discussing anti-
psychotic prescribing. Some participants recognise the
importance of working with people to reach a diagnosis in
borderline cases.
“One of the things you gain by people being in
hospital is you get the chance for a few different
people to see them err, over a period of a few days,
and that can be tremendously useful.” (Participant 3).
This could match the uncertainty that they feel with
prescribing; in comparison to the other participants they
are slow to recommend antipsychotic prescribing.
Participant nine indicated they would use other
healthcare professionals to help gather information
saying, ‘you might get some information from the GP,’
and ‘the nursing staff observe.’ However, when taking
about the treatment plan, they said, ‘then you decide,’-
which suggests they were ultimately the one to make
the decision about treatment.
Many participants worked with the patient to inform
their decisions.
‘it is important when you’re prescribing a drug to a
patient, to discuss it with them, you’ve got to talk
about their hopes, fears and expectations’. (Participant
eight)
Sub-theme 3: Putting the onus on others
Participants often shifted responsibility onto other mem-
bers of the team when they were talking about research.
‘They have done trials with a lot of antipsychotics…it’s
the commissioners and things like that, they say there
is not a lot of evidence’ (Participant 1).
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The use of the third person plural in this context sug-
gests the participant did not feel responsible for assessing
and applying research evidence to their clinical practice.
Experience
Participants refer to their clinical experience in many
ways; some frequently use the experience of previous pa-
tients to guide their clinical decisions. Others appear to
have less confidence in their clinical experience. This
theme questions how this disparity impacts prescribing.
The varying levels of experience included in this study
allows insight into what guides prescribers at different
stages of their training.
Some participants place greater emphasis on clinical
experience, while recognising that they themselves have
little clinical experience in prescribing antipsychotics.
Their clinical experience is based on what they see expe-
rienced psychiatrists do on a day-to-day basis,
“as a non-medical prescriber, it would be very, very
err, unwise I think to go against erm ... what erm,
seems to be erm, the evidence base norm amongst
experienced psychiatrists that I work with certainly.”
(participant six).
This awareness of their limited clinical experience is
emphasised by their reliance on collaboration as dis-
cussed in theme four.
Other participants discuss previous patients that they
have treated, their beliefs with regards to treatment and
assessment appear to be based on their experience with
previous patients.
“I’ve had patients who err ... presented with anorexia
and I was treating them, and then they started to
develop psychosis” (participant nine)
Integrating research evidence
This theme explores whether the data supports a hy-
pothesis that the knowledge participants have of current
clinical guidelines and published research influences the
treatment plan, or whether they rely on other factors.
Throughout this theme, it was found that participants
use evidence in varying ways.
‘There’s now this thing that you can prescribe atypical
or typical...the guidance was on atypicals, now it’s chan-
ged,’ (Participant one) recognising that neither group of
antipsychotics is superior. However, despite this know-
ledge, when discussing the plan, there was no consider-
ation of typical antipsychotics:
‘Aririprazole would be my first choice…start with
atypicals’
Other participants recognise the importance for a
prescriber to be confident about keeping up-to-date,
“I think erm, you’d have to be confident in looking at
the research evidence”. (Participant six). This state-
ment is in contrast to their lack of confidence in
their prescribing ability, where they rely on the
research.
Participant four has based their belief that patients would
rather have efficacious drugs with side effects than drugs
with reduced efficacy on evidence. They then use research,
which also follows this belief to guide their practice:
“because patients seem to want efficacy, I look at
efficacy data for antipsychotics primarily, and not just
from my own study, but from a lot of very good recent
meta-analyses.”
Other participants disagree:
“The clinical trial evidence about what they do and
don’t do is close to worthless” (participant three).
Some participants base most of their knowledge on
observation and teaching sessions, without mentioning
research evidence.
“A lot of my knowledge of antipsychotics comes from a
discussion I had with a Professor”. (Participant eight)
Compromise
This theme refers to the compromise that prescribers
make between the clinical efficacy and side effects of an-
tipsychotics. Some participants indicated that efficacy is
the most important aspect of treatment.
“Don’t do a trade-off between side effects and efficacy.
What I say is that erm ... most ... most patients are willing
to put up with significant side effects if the efficacy is good.
And they’re not willing to put up with side effects if there
is no efficacy” (Participant four).
They base this statement on a research paper which
found patients primarily want efficacy, whereas clini-
cians think that patients want to avoid side effects.
This certainty that the choice should be made on
efficacy is matched by the lack of discussion concern-
ing risk during their interview.
Others felt that the side effect profile of the drug is
more important.
“I’d be very wary of side effects” and “I would urge
caution really, and erm ... look at the erm, effectiveness
of the ... the drugs” (Participant six).
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This caution with side effects is matched by their
awareness of risk.
Discussion
The results highlight important aspects of practitioner’s rea-
soning for the way in which they prescribe antipsychotics.
All the themes identified in this study map onto aspects of
the EBM model developed by Haynes et al. [15], providing
validation of these factors. It is clear however, that partici-
pants place different weighting on each aspect.
Patient involvement
The first theme corresponds with the importance of patient’s
preferences highlighted by Haynes et al. [15]. There appears
to be a strong association between patient involvement and
the use of NICE guidelines. As discussed by Banning [13]
those with less clinical experience tend to rely more heavily
on guidelines. Therefore, this could suggest that those with
less clinical experience involve the patient more than those
with higher levels of clinical experience. Another explanation
could be that modern medical training encourages patient
involvement so those with less clinical experience are more
likely to focus more heavily on patient preference. Shared
decision-making should be advocated in all aspects of medi-
cine, however it is especially important in mental health
where there are many treatment options available, none of
which have obvious superiority [24]. As well as the obvious
ethical improvements this provides, it may have other bene-
fits such as improved adherence to treatment [25].
Ownership and collaboration
The gathering of clinical information is another factor dis-
cussed by Haynes et al. (2002) and this is assessed in the
themes. Many participants were happy to take ownership of
the information gathering process and recognised its
importance in creating a treatment plan. Other participants
recognise the importance of collaborating with other profes-
sionals to carry out a comprehensive assessment of the situ-
ation. This ties in with NICE guideline recommendations,
which suggest that other possible organic causes should be
ruled out prior to the diagnosis of schizophrenia [2]. Bradley
[11] suggested that prescribers require more information for
‘high risk’ treatments; the same appears to be true for clin-
ical scenarios. Participants who identified more risk with a
clinical scenario and the wellbeing of a patient wanted more
information and discussed diagnosis in further detail.
Experience
Haynes, Devereaux and Guyatt [15] stated that clinical ex-
pertise is needed to utilise all the information to come up
with a treatment plan. Many participants agree with the im-
portance of clinical experience. Banning [13] believes that
with experience, decision making becomes more innate and
professionals rely less on guidelines. This suggests that
professionals place great importance on what has worked
for their previous patients. It is essential that they do not
only look back to what has worked with previous patient,
but that they also look forward to the new directions of
research.
Integrating research evidence
Haynes [15] also highlights the importance of incorporating
research evidence into clinical decision making. We found
that several participants use research to guide their practice,
however only three participants said they would refer to
guidelines. Guidelines provide recommendations for the
treatment of schizophrenia and the NHS promotes their im-
plementation. The lack of implementation highlights the im-
portant reasons for conducting this study. Identification of
these factors could in the future have an impact on guideline
distribution and implementation. The implementation of
guidelines has been addressed by Rowlands [26] who sug-
gest that a strong clinical lead is needed who can distribute
the evidence and encourage its use. Implementation of evi-
dence is also addressed in Roger’s Diffusion of Innovation
[27], where it is suggested that the individual scenario must
be identified and assessed. In the UK guidelines are released
nationwide and implementation is up to individual NHS
trusts. In line with the Diffusion of Innovation, guide-
lines could be adapted to meet the needs of individ-
ual trusts or hospitals.
The participants in this study did not mention organisa-
tional issues or cost effectiveness, which have been identified
by Forsner et al. [16] as barriers to guideline implementa-
tion. This may suggest that while these barriers are import-
ant on an organisational issue they do not impact on daily
prescribing.
Compromise
The role of research is again highlighted in the final
theme, which is the compromise between side effects and
efficacy of antipsychotics. This issue has been discussed in
multiple reviews including the CATIE and CUtLass trials
[6, 8]. There is still much debate regarding the compara-
tive efficacy of different antipsychotics, however there is a
consensus on the side effects associated with particular
antipsychotics. The participants who are aware of and dis-
cuss the adverse drug reactions appear to more risk
averse. There is little evidence discussing the relationship
between prescriber’s perception of risk and the choice of
medication and whether this choice is based more heavily
on the efficacy of the drugs or their risks.
Strengths and limitations
This is the first study to qualitatively investigate the factors
involved in clinical decision-making in the context of schizo-
phrenia. These factors can be considered by organisations
when implementing guidelines so that research evidence has
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a greater influence on clinical practice, ultimately improving
patient care. Furthermore, it can help clinicians understand
more about their decision-making process, thus allowing
them to become more informed about their own clinical
practice.
In this study data saturation was reached and all pos-
sible themes identified and explored. However, the par-
ticipants were taken from the same organisation, which
may have limited the themes identified and may reduce
the generalisability of this research.
This study was conducted using thematic analysis. An
alternative method, such as Interpretative Phenomeno-
logical Analysis, may have provided a more in-depth
analysis by focusing further on individual participants.
Future directions
The results from this research can help provide
insight into some of the factors influencing clinical
decision-making. Decision aids, such as those already
used in for antidepressant prescribing created by the
Mayo Clinic [28], may be created based on these
findings to help healthcare professionals when plan-
ning treatment. Decision aids have been also been
shown to increase patient’s knowledge [29], and re-
cent evidence has shown that they are better when
used by patients and clinician’s together to foster the
shared decision making process [30] The decision
aid is likely to be in a written or electronic form,
with a potential for the role of pharmacogenetic de-
cisions aids in the future as research into the role of
these in mental health moves forward [31]. This is
important in mental health where there are many
treatment options and it is often difficult to know
which one is best for the patient.
This study can be used to guide future research into
prescribing behaviour. A Theory of Planned Behaviour
study could be used to investigate these themes further
and test the hypotheses created, for example the rela-
tionship between the perception of risk and the com-
promise between side effects and efficacy.
Conclusion
It appears that clinicians use aspects of EBM to make
clinical decisions. However, clinicians seem to place
greater emphasis on clinical experience than previously
thought. This implies that more decisions are made
using system one of unconscious competence. The im-
plications for clinical practice and for knowledge transla-
tion are that people should be encouraged to use more
of the system two to understand their own behaviour
and gain more insight into their decision-making behav-
iour. This could then be exploited when devising evi-
dence implementation processes.
Appendix
Coding Framework
Code Description
Information Patient Presentation, clinical
picture.Information from family, GP and
other sources.Further information requested
from or about the patient
Diagnosis Differential diagnosis.Seeking facts to
supportSeeking test to supportAre
participants hesitant or confident about
diagnosis
Plan How it is proposed to manage patient
Risk Risk to self or others.Risk of
recurrence.Assessing whether it is
worthwhile to take the riskRisk from
medication
Side effects vs.
Efficacy
Choice of drug – are side effects a
factor?Effectiveness of treatmentSide effects
informationUsing side effects as a treatment
strategy
Clinical Reasoning Formulating arguments to support diagnosis
or treatment plan
Clinical experience To inform diagnosis or treatmentConfidence
or a lack of confidence
Drug Information Describing the drug.Facts about its history or
method of action.
Education and
Training
Awareness of the source of their own
knowledge and practices.Changes in practice
following training and teaching
Evidence Acknowledging evidenceAssessing value and
quantity of evidence available.Using
evidence in their practice
Guidelines Acknowledging current/changes in
guidelinesUsing guidelines in their practice
Patient Involvement Considering the patient’s ideas, concerns and
expectationsIncluding the patient in
decision-makingThe influence of the patient
on the participants practiceImportance of
the patient
Own beliefs Opinions not based on specific
informationOpinions about other people’s
beliefs
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